Atosiban ( DrugBank: Atosiban )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 118 | Myelomeningocele | 1 |
118. Myelomeningocele
Clinical trials : 5 / Drugs : 7 - (DrugBank : 4) / Drug target genes : 2 - Drug target pathways : 10
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04468568 (ClinicalTrials.gov) | October 1, 2017 | 1/3/2020 | In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline | Assessment of Maternal Blood Gas Changes When Using Atosiban and Terbutaline as Tocolytic Agents, During in Utero Repair of Myelomeningocele | Myelomeningocele;Terbutaline Adverse Reaction;Pregnancy; Malformation Central Nervous System | Drug: Atosiban;Drug: Terbutaline | University of Sao Paulo General Hospital | NULL | Completed | 18 Years | 40 Years | Female | 25 | Brazil |